Loading...

APC anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14_APC_090707
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • MEL-14_APC_090707
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Save
104411 25 µg ¥9,410
104412 100 µg ¥27,590
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  2. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  3. Ferrao Blanco MN, et al. 2022. Br J Pharmacol. 179:2771. PubMed
  4. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  5. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  6. Hu X, et al. 2022. EBioMedicine. 86:104333. PubMed
  7. Dölz M, et al. 2022. iScience. 25:105372. PubMed
  8. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  9. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  10. Cowan J, et al. 2013. J Exp Med. 210:675. PubMed
  11. Ender F, et al. 2017. PLoS One. 12(2):e0172446. PubMed
  12. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  13. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  14. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  15. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  16. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  17. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
  18. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  19. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  20. Scieszka DP, et al. 2023. Respir Res. 24:138. PubMed
  21. Milighetti M, et al. 2023. iScience. 26:106937. PubMed
  22. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  23. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  24. Gabriely G, et al. 2021. iScience. 24:103347. PubMed
  25. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  26. Martens R, et al. 2020. Nat Commun. 11:1114. PubMed
  27. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  28. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  29. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  30. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  31. Rezende R, et al. 2015. Nat Commun. 6: 8726. PubMed
  32. Wang J, et al. 2012. Blood. 120:1489. PubMed
  33. Wei H, et al. 2021. Malar J. 20:89. PubMed
  34. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  35. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  36. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  37. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  38. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  39. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  40. Shapiro MR, et al. 2020. Front Immunol. 1.972222222. PubMed
  41. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  42. Zhao Y, et al. 2021. J Biol Chem. 297:101166. PubMed
  43. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  44. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  45. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  46. Wiese A, et al. 2017. PLoS One. 10.1371/journal.pone.0184956. PubMed
  47. Roy S, et al. 2020. Sci Rep. 10:10992. PubMed
  48. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  49. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  50. Li Y, et al. 2020. Nat Commun. 11:2781. PubMed
  51. Parriott G, et al. 2020. Immunology. 160:280. PubMed
  52. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  53. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  54. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  55. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  56. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  57. Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed
  58. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  59. Deng B, et al. 2022. J Immunother Cancer. 10:. PubMed
  60. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  61. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  62. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  63. Kondratieva T, et al. 2020. PLoS One. 15:e0239668. PubMed
  64. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  65. Darragh LB, et al. 2022. Nat Commun. 13:7015. PubMed
  66. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  67. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  68. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  69. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  70. Yang W, et al. 2020. Methods Mol Biol. 2111:91. PubMed
  71. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  72. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  73. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  74. Fu X, et al. 2020. Aging (Albany NY). 12:15656. PubMed
  75. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  76. Coquery C, et al. 2014. PLoS One. 9:102284. PubMed
  77. Cowan J, et al. 2014. J Immunol. 193:1204. PubMed
  78. White C, et al. 2015. J Immunol. 194:697. PubMed
  79. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  80. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  81. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  82. Morimoto Y, et al. 2018. Immunity. 49:134. PubMed
  83. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
  84. Covarrubias AJ, et al. 2020. Nat Metab. 1265:2. PubMed
  85. Ma K, et al. 2022. iScience. 25:104347. PubMed
  86. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  87. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  88. Borges da Silva H, et al. 2020. Immunity. 53(1):158-171.e6. PubMed
  89. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  90. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  91. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  92. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  93. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  94. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  95. Jenkinson W, et al. 2012. PLoS One. 7:e53416. PubMed
  96. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  97. Amezcua Vesely MC, et al. 2020. Cell. 178(5):1176-1188.e15.. PubMed
  98. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  99. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  100. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  101. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  102. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  103. Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed
  104. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  105. Schaffert S, et al. 2015. J Immunol. 195: 1470-1479. PubMed
  106. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  107. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  108. Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed
  109. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  110. Rochford I, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 321:L686. PubMed
  111. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  112. Lin JD, et al. 2020. Cell Host & Microbe. 27(5):830-840. PubMed
  113. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  114. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  115. Kooijman S, et al. 2015. Am J Physiol Heart Circ Physiol. 309: H646-H654. PubMed
  116. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  117. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  118. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  119. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  120. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  121. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  122. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
  123. Louise V Webb et al. 2019. Immunity. 50(2):348-361 . PubMed
  124. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  125. Bae S, et al. 2021. Cell Reports. 35(11):109264. PubMed
RRID
AB_313098 (BioLegend Cat. No. 104411)
AB_313098 (BioLegend Cat. No. 104412)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD62L
Specificity Alt (DOES NOT SHOW ON TDS):
CD62L
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD62L on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account